Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL337445 | 1.00 | PDK1 (0.50) | PDK1ALDH1A1MAPTLIMK1KDM4E | |
| SCHEMBL14328268 | 1.00 | PDK1 (0.50) | PDK1ALDH1A1MAPTLIMK1KDM4E | |
| SCHEMBL24565374 | 0.89 | ALDH1A1 (0.47) | PDK1ALDH1A1MAPTKDM4EKMT2A | |
| SCHEMBL141713 | 0.89 | ALDH1A1 (0.47) | PDK1ALDH1A1MAPTKDM4EKMT2A | |
| SCHEMBL5483 | 0.89 | ALDH1A1 (0.51) | PDK1ALDH1A1MAPTKDM4EKMT2A | |
| SCHEMBL9097897 | 0.88 | ALDH1A1 (0.49) | PDK1ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL19816460 | 0.86 | PPM1B (0.41) | PDK1ALDH1A1MAPTLIMK1KDM4E | |
| SCHEMBL19816450 | 0.86 | PPM1B (0.41) | PDK1ALDH1A1MAPTLIMK1KDM4E | |
| Ethylene SCHEMBL4705578 | 0.85 | ALDH1A1 (0.49) | PDK1ALDH1A1MAPTKDM4EKMT2A | |
| SCHEMBL871448 | 0.84 | ALDH1A1 (0.50) | PDK1ALDH1A1MAPTKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-25 | — | — | US | disclosed |
| US-9738629-B2 | Bridged ring compounds as Hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-08-22 | — | — | US | disclosed |
| US-20170044140-A1 | BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | VIM, ACE, ACE2 | PDK1 3592/4885ALDH1A1 1895/4885MAPT 1072/4885 |
| US-20170044140-A1 | BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SLC10A1, CYP7A1, CYP3A43 | PDK1 3471/4885ALDH1A1 1169/4885MAPT 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.